Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors

Stock Information for ClearPoint Neuro, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ClearPoint Neuro, Inc.

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza(TM) as a Treatment for AADC Deficiency
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
ClearPoint Neuro Launches Proposed Public Offering of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.